Compare NSSC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | SDGR |
|---|---|---|
| Founded | 1969 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1994 | 2020 |
| Metric | NSSC | SDGR |
|---|---|---|
| Price | $35.63 | $15.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $48.17 | $21.00 |
| AVG Volume (30 Days) | 322.2K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ 0.70 | N/A |
| Revenue | $181,621,000.00 | ★ $255,869,000.00 |
| Revenue This Year | $13.63 | $0.76 |
| Revenue Next Year | $10.05 | $4.60 |
| P/E Ratio | $50.94 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $29.27 | $10.95 |
| 52 Week High | $47.61 | $23.02 |
| Indicator | NSSC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 44.62 |
| Support Level | $34.58 | $11.27 |
| Resistance Level | $38.58 | $16.47 |
| Average True Range (ATR) | 1.06 | 0.69 |
| MACD | -0.09 | -0.24 |
| Stochastic Oscillator | 30.94 | 17.60 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.